Bicalutamide as an Androgen Blocker With Secondary Effect of Promoting Feminization in Male-to-Female Transgender Adolescents by Neyman, Anna et al.
Bicalutamide as an Androgen Blocker With Secondary Effect of 
Promoting Feminization in Male-to-Female Transgender 
Adolescents
Anna Neyman, M.D.*, John S. Fuqua, M.D., and Erica A. Eugster, M.D.
Department of Pediatrics, Indiana University School of Medicine and Riley Hospital for Children, 
Indianapolis, Indiana
Abstract
Purpose: The purpose of the study was to describe the novel use of bicalutamide in transgender 
youth.
Methods: This is a retrospective review of patients with gender dysphoria followed in the 
pediatric endocrine clinic at Riley Hospital for Children.
Results: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received 
bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a 
gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 
patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development 
within 6 months, the majority being ≥ Tanner stage III.
Conclusions: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in 
transgender male-to-female youth who are also ready to undergo physical transition.
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Guidelines for the treatment of adolescents with gender dysphoria (GD) include the use of 
puberty blockers to suppress the reproductive system and prevent secondary sexual 
development contrary to the individual’s affirmed gender [1]. Gonadotropin-releasing 
hormone analogs (GnRHas) are considered the gold standard for halting pubertal 
development in these youth [1]. However, insurance coverage for GnRHas for this indication 
varies widely. When these expensive medications are denied by third-party payers or when 
the copay is prohibitively expensive, other options are needed to be able to provide 
appropriate care for transgender adolescents. In addition to halting pubertal progression, 
embarking on physical transition that is aligned with gender identity is frequently expressed 
by patients as a goal when starting endocrine treatment [2].
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The potent androgen receptor blocker bicalutamide represents a potential alternative 
approach to GnRHas in natal males. Other antiandrogens used in transgender females 
include spironolactone and cyproterone acetate. However, both are far less potent than 
bicalutamide and their use has primarily been limited to adults [1,3]. In contrast, 
bicalutamide has been used in the treatment of familial male precocious puberty and other 
forms of peripheral precocious puberty in young boys [4–6]. One of the most common side 
effects of bicalutamide is breast development due to an alteration in the ratio of androgens to 
estrogens. Our experience with the use of bicalutamide in precocious puberty formed the 
basis for the use of this medication in male-to-female (MTF) patients with GD as a strategy 
for blocking puberty when GnRHas are denied. Interestingly, the resulting “side effect” of 
breast development has been welcomed by these patients, all of whom are eager to receive 
cross-hormone treatment (in this case, estrogen) and to undergo feminizing changes. We are 
not aware of any previous reports of utilizing bicalutamide as a way to block puberty and 
promote feminization in the transgender MTF population.
Methods
After institutional review board approval, medical records of patients with GD followed in 
the pediatric endocrine clinic at Riley Hospital for Children were reviewed. Inclusion criteria 
included MTF transgender patients who were treated with bicalutamide. Variables evaluated 
comprised age, ethnicity, duration of follow-up, timing of estrogen initiation, laboratory 
studies, and change in breast Tanner stage during treatment. GraphPad Prism, version 7.03, 
(GraphPad Software) was used for statistical analyses of sample data.
Results
Of 104 patients with GD, 39 (37.5%) were MTF patients. Of these, 23 (59%) aged 16 ± 1.77 
(range 12–18.4) years were treated with bicalutamide 50 mg daily between 2013 and 2018. 
All but one were Caucasian. The median age when starting bicalutamide was 16.63 years. 
Seventeen received bicalutamide alone whereas six were started on estrogen concurrently. 
Fifteen patients who were started on bicalutamide alone have been seen in follow-up thus 
far. Of these, 1 was briefly on spironolactone and 1 was started on estrogen after 2 months 
on bicalutamide. Both of these patients were excluded from further analysis. The majority of 
the patients were prescribed bicalutamide as a second line after GnRHas were denied. 
However, there were some older patients who chose bicalutamide with the possible 
secondary feminizing effect in mind. At the first follow-up visit, which occurred at a median 
of 6.3 months after starting treatment, 84.6% of the patients had breast development, which 
ranged from Tanner stage II-V. Of the 2 patients who remained Tanner stage I, one had only 
been taking bicalutamide for 2 months and the other patient progressed to Tanner stage III at 
the second follow-up visit 12.5 months after starting bicalutamide. Thus, 100% of patients 
experienced breast development while on bicalutamide alone. All but 3 patients had 
laboratory studies obtained during the course of treatment with bicalutamide. Liver function 
tests (LFTs) were measured at baseline in 3 patients and between 6.3 and 29.3 months after 
starting bicalutamide in the remainder. Five patients had >1 set of LFTs drawn, and all were 
normal. Sex steroids were obtained in a subset of patients being treated exclusively with 
bicalutamide. Estradiol concentrations (n = 6) were <20–61 pg/dl and testosterone levels (n 
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= 5) ranged between 524 and 823 ng/dl. One patient had a baseline testosterone of 220.6 
ng/dl which rose to 693.8 ng/dl when next measured at 14.3 months. Clinical and laboratory 
characteristics of patients treated with bicalutamide are summarized in Table 1. Subjectively 
reported effects of bicalutamide included decreased acne and reduced frequency of shaving. 
Anecdotally, all patients were extremely positive regarding the breast development they 
experienced on bicalutamide therapy.
Discussion
Bicalutamide is used in rare forms of precocious puberty in boys and has a known side effect 
of gynecomastia. Here, we report the novel use of bicalutamide as a puberty blocker in MTF 
patients with GD in whom it also results in feminization by causing breast development. To 
our knowledge, we are the first to report the use of bicalutamide in this setting.
We have found that bicalutamide appears to be effective in decreasing androgen exposure 
with the welcome side effect in these adolescents of promoting feminization. We suspect 
that the relatively rapid breast enlargement is because of the high potency and purely 
antagonistic action of bicalutamide on the androgen receptor, leading to increased 
testosterone levels that are subsequently aromatized to estrogen. In those tested, liver 
enzymes remained normal, and estradiol levels were above 20 pg/dl with only one 
exception. There were no apparent adverse effects of bicalutamide in our patients. However, 
our results must be considered extremely preliminary, and additional data are needed. How 
bicalutamide might compare to other androgen receptor blockers in terms of safety and 
efficacy in the adolescent age group is unknown, and the risk for liver toxicity needs to be 
investigated in larger sample sizes and over a longer duration of time.
The limitations of this study are its small size, minimal laboratory testing, and retrospective 
nature. Another limitation is that the efficacy of androgen suppression can only be 
monitored clinically, as testosterone levels actually increase. However, our results suggest 
that bicalutamide may be an option for transgender MTF adolescents who are denied 
GnRHas and are also ready for physical feminization. Bicalutamide is also significantly less 
costly than GnRHas, which costs thousands of dollars per dose. Larger, prospective studies 
with a more diverse patient population are needed to further evaluate the safety and potential 
role of bicalutamide in the therapeutic armamentarium for the treatment of transgender MTF 
youth.
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IMPLICATIONS AND CONTRIBUTION
Gonadotropin-releasing hormone analogs are often prohibitively expensive necessitating 
the use of alternative puberty blockers in children with gender dysphoria. This study 
reports on the use of bicalutamide in male-to-female youth, in whom it also causes 
significant feminization.
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